Apo-Methylphenidate ER — Competitive Intelligence Brief

Apo-Methylphenidate ER (Apo-Methylphenidate ER) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sympathomimetic amine; central nervous system stimulant. Area: Psychiatry / Neurology.

phase 2 Sympathomimetic amine; central nervous system stimulant Dopamine transporter (DAT); Norepinephrine transporter (NET) Psychiatry / Neurology Small molecule

Target snapshot

Apo-Methylphenidate ER (Apo-Methylphenidate ER) — The Royal Ottawa Mental Health Centre. Methylphenidate is a central nervous system stimulant that increases dopamine and norepinephrine activity in the brain by blocking their reuptake at the synapse.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Apo-Methylphenidate ER TARGET	Apo-Methylphenidate ER	The Royal Ottawa Mental Health Centre	phase 2	Sympathomimetic amine; central nervous system stimulant	Dopamine transporter (DAT); Norepinephrine transporter (NET)
Propadrine	PHENYLPROPANOLAMINE	Alpharma Us Pharms	marketed	Indirectly Acting Sympathomimetic Amines	Sodium-dependent noradrenaline transporter	2000-01-01
Didrex	BENZPHETAMINE	Pfizer	marketed	Sympathomimetic Amine Anorectic	Alpha-1A adrenergic receptor	1960-01-01
Tenuate	DIETHYLPROPION	ANI Pharmaceuticals	marketed	Sympathomimetic Amine Anorectic	Sodium-dependent dopamine transporter	1959-01-01
Aramine	METARAMINOL		marketed	Indirectly Acting Sympathomimetic Amines	Macrophage migration inhibitory factor	1954-01-01
Vialin	MEPHENTERMINE	Baxter	marketed	Indirectly Acting Sympathomimetic Amines	Alpha-1A adrenergic receptor	1951-01-01
epinephrine perfusion	epinephrine perfusion	Central Hospital, Nancy, France	marketed	Sympathomimetic amine / Catecholamine	Alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sympathomimetic amine; central nervous system stimulant class)

1. Children's Hospital Medical Center, Cincinnati · 1 drug in this class
2. Hospital de Clinicas de Porto Alegre · 1 drug in this class
3. Oregon Health and Science University · 1 drug in this class
4. Orient Pharma Co., Ltd. · 1 drug in this class
5. Pfizer · 1 drug in this class
6. St. Louis University · 1 drug in this class
7. The Royal Ottawa Mental Health Centre · 1 drug in this class
8. UCB Pharma · 1 drug in this class
9. University of California, San Francisco · 1 drug in this class
10. University of Utah · 1 drug in this class